Reason #4: We dont know enough yet This is perhaps the most honest reason: the absence of data isnt the same as data showing safety
It is estimated that PD affects at least 1% of the population over the age of 60 (Zafar and Yaddanapudi, 2023)
Common administration methods include: Subcutaneous injections (most common, high bioavailability) Oral capsules (for peptides stable in digestion) Nasal sprays (for neuro-targeted peptides) Topical creams (for skin and soft tissue concerns) Treatment is often personalized , with protocols tailored to individual goals (e.g., muscle growth, anti-aging, healing), and monitored via lab tests to ensure optimal dosing and outcomes
One promising solution is to pair GLP-1 therapies with agents that block negative muscle regulators like activin receptor type II (ActRII) and ligands such as GDF8 (myostatin) and activin A
Deneke SM, Fanburg BL, 1989